Products Categories
| CAS No.: | 7681-11-0 |
|---|---|
| Name: | Potassium iodide |
| Article Data: | 261 |
| Molecular Structure: | |
|
|
|
| Formula: | KI |
| Molecular Weight: | 166.003 |
| Synonyms: | Dipotassium diiodide;Thyro-Block;Thyroblock;Pima;KI;Kaiod;Potide;K1-N;Potassium iodide (K(I2));Joptone;Mudrane-2 Tablets;Potassium iodide [JAN];Potassium monoiodide;Potassium salt of hydriodic acid;Iodure de potassium;Kaliumiodid;Pherajod;Kalii iodidum;Kali iodide;Potassium iodide (KI);Potassium diiodide;Tripotassium triiodide;Potassium iodide (JP14/USP);3,4,5-Trihydroxy benzoic acid;Potassium Iodide 45% Soln;Thyroblock (TN);Knollide;Kisol;Asmofug E;Mudrane Tablets;Potassium iodide (K2I2); |
| EINECS: | 231-659-4 |
| Density: | 1.32 g/mL at 25 °C |
| Melting Point: | 113 °C(lit.) |
| Boiling Point: | 184 °C(lit.) |
| Flash Point: | 1330°C |
| Solubility: | 1.43 kg/L in water |
| Appearance: | white to off-white crystalline powder |
| Hazard Symbols: |
 Xn, Xi, N
|
| Risk Codes: | 36/37/38-36/37-20/21/22-19-11-43-34-20/21-42/43-36/38-61 |
| Safety: | 24/25 |
| Transport Information: | UN 2056 3/PG 2 |
| PSA: | 0.00000 |
| LogP: | -2.99600 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
| Conditions | Yield |
|---|---|
| In ethanol Kinetics; shaking for 2-3 days;; | A 80% B n/a |
| In ethanol Kinetics; at 100°C;; | A >99 B n/a |
A
- 256428-54-3
(Cp3i)2Pb
B
- 7681-11-0
potassium iodide
| Conditions | Yield |
|---|---|
| In tetrahydrofuran KCp3i and PbI2 were added to THF and suspn. was stirred for 12 h; THF was removed under vac., residue was extd. with hexane, filtered andhexane was removed; | A 68% B n/a |
- 17084-13-8
potassium hexafluorophosphate
- 70460-15-0
[CpFe(dppe)(CN)]
- 74-88-4
methyl iodide
A
- 174904-18-8
[CpFe(dppe)(η(1)-CNCH3)]PF6
B
- 7681-11-0
potassium iodide
| Conditions | Yield |
|---|---|
| In tetrahydrofuran addn. of KPF6 and MeI to soln. of Fe complex, stirring (room temp., 14 h), filtration, solvent removal (vac.); extn. into CH2Cl2, concn. (vac.), pptn. on Et2O addn., washing (Et2O); elem. anal.; | A 60% B n/a |
| Conditions | Yield |
|---|---|
| potassium polymanganite(IV) In solid byproducts: O2; mixt. of KIO3 and potassium polymanganate heated (400-600°C, 2h, air); X-ray diffraction; | A 1% B n/a |
| Conditions | Yield |
|---|---|
| With potassium hydroxide In not given evaporation of solvent then glowing, remainder of KOH neutralized with HI; | |
| With potassium sulfite; potassium carbonate In not given byproducts: K2SO4, CO2; iodine containing activated charcoal and theoretic amounts of K2CO3 and K2SO3 used; filtration, evaporation of solvent; | |
| With potassium hydroxide; hydrogen sulfide In not given soln. of KOH saturated with I2, then H2S introduced into soln. of iodide-iodite; |
| Conditions | Yield |
|---|---|
| With potassium sulfide In water solid K2S used; evaporation of solvent; | |
| With potassium sulfide In ethanol solid K2S used; evaporation of solvent; |
| Conditions | Yield |
|---|---|
| With potassium carbonate In not given filtration and evaporation of solvent; |
| Conditions | Yield |
|---|---|
| In not given on presence of water;; |
| Conditions | Yield |
|---|---|
| luminous phenomenon and development of heat; | |
| In neat (no solvent) 400 up to 500 °C;; | |
| In neat (no solvent) 400 up to 500 °C;; |
| Conditions | Yield |
|---|---|
| In neat (no solvent) primary reactn. in high dild. flames;; | |
| In neat (no solvent) primary reactn. in high dild. flames;; |
- 128-44-9Saccharinsodium
- 3458-28-4D-(+)-Mannose
- 1344-28-1Aluminum oxide
- 56-87-1L-Lysine
- 94-09-7Benzoicacid, 4-amino-, ethyl ester
- 317318-70-0Aceticacid, [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-(9CI)
- 111-76-2Ethanol,2-butoxy-
- 8001-79-4Castor oil
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
Potassium iodide , with CAS number of 7681-11-0, can be called AI3-52931; Asmofug E; Dipotassium diiodide; Iodure de potassium; Potassium monoiodide; Thyro-Block; Potide; Tripotassium triiodide. Potassium iodide is an inorganic compound with the chemical formula KI. KI is also used as a fluorescence quenching agent in biomedical research because of collisional quenching by its iodide ion. Potassium iodide is used medicinally in tablets.Potassium iodide is an inorganic compound with formula KI.
Properties about Potassium iodide are: (1)mp:113 °C(lit.); (2)bp: 184 °C(lit.); (3)density: 1.32 g/mL at 25 °C; (4)vapor density: 9 (vs air); (5)vapor pressure: 0.31 mm Hg ( 25 °C); (6)refractive index: 1.677; (7)Fp: 1330°C; (8)storage temp. : Store at RT.; (9)solubility H2O: 1 M at 20 °C, clear, colorless; (10)Water Solubility: 1.43 kg/L; (11)Merck: 14,7643
Preparation of Potassium iodide: Potassium iodide is ionic, K+I−. It crystallises in the sodium chloride structure. It is produced industrially by treating KOH with iodine.
Uses of Potassium iodide: Potassium iodide is used to loosen and break up mucus in the airways. This helps you cough up the mucus so you can breathe more easily if you have long-term lung problems (e.g., asthma, chronic bronchitis, emphysema). This medication is known as an expectorant.
Potassium iodide is also used along with antithyroid medicines to prepare the thyroid gland for surgical removal, to treat certain overactive thyroid conditions (hyperthyroidism), and to protect the thyroid in a radiation exposure emergency. It works by shrinking the size of the thyroid gland and decreasing the amount of thyroid hormones produced.
When you are using this chemical, please be cautious about it as the following:
1. Avoid contact with skin and eyes;
2. Wear suitable protective clothing;
3. In case of accident or if you feel unwell, seek medical advice immediately (show label where possible);
4. Wear suitable protective clothing, gloves and eye/face protection;
You can still convert the following datas into molecular structure:
(1)InChI=1S/HI.K/h1H;/q;+1/p-1;
(2)InChIKey=NLKNQRATVPKPDG-UHFFFAOYSA-M;
(3)Smiles[K+].[I-];
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LDLo | intraperitoneal | 1117mg/kg (1117mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Journal of Pharmacology and Experimental Therapeutics. Vol. 120, Pg. 171, 1957. |
| mouse | LDLo | oral | 1862mg/kg (1862mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Journal of Pharmacology and Experimental Therapeutics. Vol. 120, Pg. 171, 1957. |
| rabbit | LDLo | oral | 916mg/kg (916mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 30, Pg. 407, 1927. | |
| rat | LDLo | intravenous | 167mg/kg (167mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 96, Pg. 292, 1923. |